These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38598900)

  • 21. Human epididymis protein 4 reference intervals in a multiethnic asian women population.
    Mokhtar N; Thevarajah M; Ma N; M I
    Asian Pac J Cancer Prev; 2012; 13(12):6391-5. PubMed ID: 23464464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of serum HE4 levels in various histologic subtypes of epithelial ovarian cancer and other malignant tumors.
    Blackman A; Mitchell J; Rowswell-Turner R; Singh R; Kim KK; Eklund E; Skates S; Bast RC; Messerlian G; Miller MC; Moore RG
    Tumour Biol; 2021; 43(1):355-365. PubMed ID: 34957977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential association between elevated serum human epididymis protein 4 and chronic kidney disease in female patients.
    Meng ZJ; Li XJ; Liu F; Li RS; Liang HP
    J Physiol Pharmacol; 2020 Dec; 71(6):. PubMed ID: 33901997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
    Ahmed AA; Abdou AM
    Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Epididymis Protein 4 as a Potential Biomarker of Chronic Kidney Disease in Female Patients With Normal Ovarian Function.
    Yuan T; Li Y
    Lab Med; 2017 Aug; 48(3):238-243. PubMed ID: 28934517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
    Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas.
    Simmons AR; Baggerly K; Bast RC
    Oncology (Williston Park); 2013 Jun; 27(6):548-56. PubMed ID: 23909069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
    Dewan R; Dewan A; Jindal M; Bhardawaj M
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker.
    Machida H; Hirakawa T; Tsunekawa K; Kimura T; Murakami M; Abe Y
    Gynecol Obstet Invest; 2023; 88(6):349-358. PubMed ID: 37788640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CPH-I and HE4 Are More Favorable Than CA125 in Differentiating Borderline Ovarian Tumors from Epithelial Ovarian Cancer at Early Stages.
    Wang Z; Tao X; Ying C
    Dis Markers; 2019; 2019():6241743. PubMed ID: 31737130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disorders.
    Zhang Y; Qiao C; Li L; Zhao X; Li Y
    Afr Health Sci; 2014 Dec; 14(4):913-8. PubMed ID: 25834501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
    Zhang L; Chen Y; Wang K
    Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic performance of HE4 and ROMA among Chinese women.
    Shen Y; Zhao L; Lu S
    Clin Chim Acta; 2020 Jan; 500():42-46. PubMed ID: 31626761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Usefulness of Cancer Antigen (CA) 125, Human Epididymis 4, and CA72-4 Levels and Risk of Ovarian Malignancy Algorithm Values for Diagnosing Ovarian Tumors in Korean Patients With and Without Endometriosis.
    Shin KH; Kim HH; Kwon BS; Suh DS; Joo JK; Kim KH
    Ann Lab Med; 2020 Jan; 40(1):40-47. PubMed ID: 31432638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors.
    Sai Baba KSS; Rehman MA; Pradeep Kumar J; Fatima M; Raju GSN; Uppin SG; Mohammed N
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2509-2507. PubMed ID: 34452565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings.
    Wilailak S; Chan KK; Chen CA; Nam JH; Ochiai K; Aw TC; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Charakorn C; Sumpaico WW
    J Gynecol Oncol; 2015 Jan; 26(1):46-53. PubMed ID: 25310857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of human epididymis 4, D-dimer, and fibrinogen compared with CA 125 alone in triaging women presenting with pelvic masses: a retrospective cohort study.
    McKendry K; Duff S; Huang Y; Redha M; Scanlon Á; Abu Saadeh F; Gleeson N; O'Leary J; Norris L; O'Toole S
    Acta Obstet Gynecol Scand; 2021 Jul; 100(7):1239-1247. PubMed ID: 33590896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
    Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.